The situation of mucosal and acral melanoma patients is further complicated by the fact that these tumors are often triple wild-type tumors, i.e., without a BRAFV600E/K, NRAS or NF1 mutation, and therefore not qualified for targeted therapy with BRAF and MEK inhibitors. Here, BRAF is linked to acral lentiginous melanoma.